Qlife Holding AB, Interim report Q3, January to September 2023
Looking ahead with new partnersFinancial summary – third quarter 2023 · Revenue in the period amounted to kSEK 45 (1,967). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q3 is solely from test orders ofCRP capsules and Egoo systems. · EBITDA for the period amounted to kSEK -6,660 (-14,850), and net loss kSEK -8,926(-20,678). · The total cash flow in the third quarter amounted to kSEK -3,631 (-21,766). · Earnings per share before/after dilution for the quarter amounted to SEK -0,01 (-1.34),calculated on weighted average number of